Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)

Next Previous
Trial Profile

A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; DSP 107 (Primary)
  • Indications Carcinoma; Colorectal cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors KAHR Medical

Most Recent Events

  • 02 Jun 2025 According to a KAHR Medical Media Release, data from Phase 2 dose expansion cohort in Non-small Cell Lung Cancer (NSCLC) expected in 2026.
  • 02 Jun 2025 According to a KAHR Medical Media Release, data from the Phase 2 dose expansion cohort of the study were presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, May 30 -June 3, 2025, in Chicago, IL.
  • 02 Jun 2025 Results (at data cut off May 2025, n=40) presented in the KAHR Medical Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top